Have a feature idea you'd love to see implemented?
Let us know!
GTBP GT Biopharma Inc
Price (delayed)
$3.01
Market cap
$6.73M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$7.38
Enterprise value
$214,327
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based our proprietary TriKE™ NK cell engager platform. Our TriKE™ platform
Highlights
The debt has shrunk by 100% YoY
GTBP's EPS is up by 15% year-on-year and by 3.1% since the previous quarter
GT Biopharma's equity has shrunk by 79% YoY and by 62% QoQ
GT Biopharma's quick ratio has shrunk by 56% YoY and by 43% QoQ
Key stats
What are the main financial stats of GTBP
Market
Valuations
Earnings
Shares outstanding
2.23M
Market cap
$6.73M
Enterprise value
$214,327
Price to earnings (P/E)
N/A
Price to book (P/B)
3.21
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$12.35M
EBITDA
-$12.35M
Free cash flow
-$12.48M
Per share
Balance sheet
Liquidity
EPS
-$7.38
Free cash flow per share
-$5.59
Book value per share
$0.94
Revenue per share
$0
TBVPS
$3.03
Total assets
$6.76M
Total liabilities
$4.66M
Debt
$0
Equity
$2.1M
Working capital
$2.1M
Debt to equity
0
Current ratio
1.45
Quick ratio
1.4
Net debt/EBITDA
0.53
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-123.3%
Return on equity
-242.2%
Return on invested capital
-2,919.4%
Return on capital employed
-588.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GTBP stock price
How has the GT Biopharma stock price performed over time
Intraday
-5.64%
1 week
0%
1 month
24.38%
1 year
-56.38%
YTD
-60.65%
QTD
30.36%
Financial performance
How have GT Biopharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$13.77M
Net income
-$12.35M
Gross margin
N/A
Net margin
N/A
The company's net income fell by 21% YoY and by 9% QoQ
GTBP's operating income is up by 15% year-on-year but it is down by 3.6% since the previous quarter
Growth
What is GT Biopharma's growth rate over time
Valuation
What is GT Biopharma stock price valuation
P/E
N/A
P/B
3.21
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
GTBP's EPS is up by 15% year-on-year and by 3.1% since the previous quarter
The price to book (P/B) is 129% higher than the last 4 quarters average of 1.4
GT Biopharma's equity has shrunk by 79% YoY and by 62% QoQ
Efficiency
How efficient is GT Biopharma business performance
GTBP's ROE has dropped by 176% year-on-year and by 51% since the previous quarter
The company's return on assets has shrunk by 114% YoY and by 34% QoQ
Dividends
What is GTBP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GTBP.
Financial health
How did GT Biopharma financials performed over time
GT Biopharma's total assets is 45% more than its total liabilities
GT Biopharma's total assets has plunged by 58% YoY and by 27% from the previous quarter
GT Biopharma's quick ratio has shrunk by 56% YoY and by 43% QoQ
The debt is 100% lower than the equity
The debt has shrunk by 100% YoY
The company's debt to equity has shrunk by 100% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.